Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa: A Study on Population Pharmacokinetics with Monte Carlo Simulations

Roscovitine (Seliciclib), a new protein kinase inhibitor, was administered orally to adult patients with cystic fibrosis for the first time in the ROSCO-CF trial, a dose-escalation, phase IIa, randomized, controlled trial. Extensive pharmacokinetic sampling was performed up to 12 h after the first o...

Descripción completa

Detalles Bibliográficos
Autores principales: Leven, Cyril, Schutz, Sacha, Audrezet, Marie-Pierre, Nowak, Emmanuel, Meijer, Laurent, Montier, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696167/
https://www.ncbi.nlm.nih.gov/pubmed/33198319
http://dx.doi.org/10.3390/pharmaceutics12111087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696167/
https://www.ncbi.nlm.nih.gov/pubmed/33198319
http://dx.doi.org/10.3390/pharmaceutics12111087

Ejemplares similares